Sanderson et al. (2001a) demonstrated that atrazine and its mono-dealkylated metabolites (DEA and DIA) also increased aromatase activity. The di-dealkylated metabolite (DACT) was inactive at concentrations up to 30 μM. Sanderson et al. (2001a) compared aromatase activity in H295R cells, JEG-3 placental cells, and MCF-7 breast cancer cell lines after exposure to chlorotriazine in vitro. The gene discussed is CYP19A1; the disease is breast carcinoma.